EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The trichotomy of HER2 expression confers new insights into the understanding and managing for breast cancer stratified by HER2 status

Mingxia Jiang, Jiaxuan Liu, Qiao Li iD, Binghe Xu iD

International Journal of Cancer · 2023

DOI: 10.1002/ijc.34570 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Cancer, 2023. Verfasst von Mingxia Jiang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Scien…. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 94 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human epidermal growth factor receptor 2 (HER2) is a tyrosine kinase receptor that plays a carcinogenic role in breast cancer (BC) through gene amplification, mutation, or overexpression. Traditional methods of HER2 detection were divided into positive (immunohistochemistry (IHC) 3+/fluorescence in situ hybridization (FISH) amplification) and negative (IHC 2+/FISH−, IHC 1+, IHC 0) according to the dichotomy method. Anti‐HER2‐targeted therapies, such as trastuzumab and pertuzumab, have significantly improved the prognosis of HER2‐positive patients. However, up to 75% to 85% of patients remain HER2‐negative. In recent years, with the rapid development of molecular biology, gene detection technology, targeted therapy, and immunotherapy, researchers have actively explored the clinicopathological characteristics, molecular biological characteristics, treatment methods, and HER2 detection methods of HER2‐low/zero breast cancer. With the clinical efficacy of new anti‐HER2 targeted drugs, accurate classification of breast cancer is very important for the treatment choice. Therefore, the following review summarizes the necessity of developing HER2 detection methods, and the clinicopathological and drug treatment characteristics of patients with HER2‐low/zero, to light the dawn of the treatment of breast cancer patients with HER2‐low/zero expression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsHumansFemaleIn Situ Hybridization, FluorescenceErb-b2 Receptor Tyrosine KinasesTrastuzumabPrognosisTreatment OutcomeGene Amplification

Stichwörter der Autor:innen

HER2-low expressionHER2-zero expressionIHCbreast cancertherapy

Substanzen

Erb-b2 Receptor Tyrosine KinasesTrastuzumab

Autor:innen und Institutionen

  • Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

ORCID-Profile: Qiao Li, Binghe Xu

Zitieren

APA

Jiang, M., Liu, J., Li, Q., & Xu, B. (2023). The trichotomy of HER2 expression confers new insights into the understanding and managing for breast cancer stratified by HER2 status. International Journal of Cancer. https://doi.org/10.1002/ijc.34570

Vancouver

Jiang M, Liu J, Li Q, Xu B. The trichotomy of HER2 expression confers new insights into the understanding and managing for breast cancer stratified by HER2 status. International Journal of Cancer. 2023. doi:10.1002/ijc.34570

BibTeX
@article{Jiang2023,
  author = {Jiang, Mingxia and Liu, Jiaxuan and Li, Qiao and Xu, Binghe},
  title = {The trichotomy of HER2 expression confers new insights into the understanding and managing for breast cancer stratified by HER2 status},
  journal = {International Journal of Cancer},
  year = {2023},
  doi = {10.1002/ijc.34570}
}
Kostenlos starten →